Print This Page
Telmisartan Tablets pictures & photos
Telmisartan Tablets pictures & photos
Telmisartan Tablets pictures & photos
Telmisartan Tablets pictures & photos
Telmisartan Tablets pictures & photos
Telmisartan Tablets pictures & photos
  • Telmisartan Tablets
  • Telmisartan Tablets
  • Telmisartan Tablets
  • Telmisartan Tablets
  • Telmisartan Tablets
  • Telmisartan Tablets
Favorites

Telmisartan Tablets

Reference FOB Price / Purchase Qty.
Get Latest Price
US $2.92
2-99 Pieces
US $2.11
100-999 Pieces
US $1.38
1,000+ Pieces
Name: Telmisartan
Name1: Telmisartan Tablets
Name3: Telmisartan1
Name4: Telmisartan Tablets2
Transport Package: Carton
Specification: 20x15x15cm
Samples:
US$ 50/Piece 1 Piece(Min.Order)
| Request Sample
Customization:
Available
| Customized Request
ITB Biopharm Co., Ltd.
Diamond Member Since 2020

Suppliers with verified business licenses

Rating: 4.5/5
Trading Company

Product Description

Company Info.
  • Overview
  • Company Profile
Overview

Basic Info.

Model NO.
HT222
Trademark
FUL
Origin
China
Production Capacity
100000/Month

Product Description



Telmisartan Tablets
Generic name: Telmisartan tablet

Telmisartan Tablets

Chinese pinyin: TelmisartanTablets

Ingredient < P > The main ingredient of this product is telmisartan.

[Properties] This product is white or quasi-white.
         

[Indication] for the treatment of essential hypertension.

[Usage and Dosage] 1. Adults: The drug should be given individually, and the usual initial dose is 1 tablet. This product can be used together with thiazide diuretics such as hydrochlorothiazide, which have synergistic antihypertensive effect with this product. Since telmisartan is most effective after 4 to 8 weeks of administration, this should be considered when increasing the dose.

2. Patients with renal insufficiency: patients with mild or moderate renal impairment do not need to adjust the dose of this product. Telmisartan cannot be eliminated by hemodialysis.

3. Patients with hepatic insufficiency: For patients with mild or moderate hepatic insufficiency, the daily dosage of this product should not exceed 1 tablet.

4. The elderly: take this product without adjusting the dose.

5. Children and adolescents: Data on the safety and efficacy of this product for children and adolescents under 18 years of age have not been established.

[Adverse reactions] Adverse reactions were divided into: very common (1/10); Common (1/100, 1/10); Rare (1/1000, 1/100); Rare (1/10,000, 1/1000); Very rare (1 in 10,000). 1. Systemic reactions. Common: back pain (e.g. sciatica), chest pain, flu-like symptoms, symptoms of infection (e.g. urinary tract infection including cystitis). Rare: abnormal vision and perspiration. Central and peripheral nervous system: Common: vertigo. 3. Gastrointestinal system: Common: abdominal pain, diarrhea, indigestion, gastrointestinal dysfunction. Rare: abnormal vision and perspiration. 4. Musculoskeletal system: Common: joint pain, leg cramps or leg pain, myalgia. Nervous system: Rare: anxiety. Respiratory system: Common: Upper respiratory tract infections include pharyngitis and rhinitis. 7. Skin and accessory systems: Common: Skin abnormalities such as eczema. 8. In addition, erythema, pruritus, syncope, insomnia, depression, stomach discomfort, vomiting, hypotension, bradycardia, tachycardia, dyspnea, eosinophilia, thrombocytopenia, weakness and decreased work efficiency have been reported in individual cases since telmisartan was marketed. Similar to other angiotensin antagonists, angioedema, urticaria, and other related adverse reactions have been reported in a few cases.

[Contraindication] 1. Allergic to the active ingredient or any excipient. 2. Middle and end of pregnancy and breastfeeding. 3. Patients with biliary obstruction disease. 4. Patients with severe liver insufficiency. 5. Patients with severe renal dysfunction (creatinine clearance rate 30ml/ min).

1. Liver insufficiency: This product should not be used in patients with cholestasis, biliary obstruction disease or severe liver dysfunction, because telmisartan is mostly excreted through bile, and the clearance rate of this product in these patients may be reduced. This product should be used with caution in patients with mild to moderate hepatic insufficiency. 2. Nephrovascular hypertension: Drugs that affect the renin-angiotensin-aldosterone system are associated with an increased risk of severe hypotension and renal insufficiency in bilateral renal artery stenosis or in a single case of functional renal artery stenosis. 3. Renal insufficiency and renal transplant patients: this product should not be used in patients with severe renal insufficiency (creatinine clearance 30ml/min, see contraindications). For patients with renal insufficiency, blood potassium and creatinine levels should be measured regularly during the use of this product. There is no data on the use of this product in patients shortly after recent kidney transplantation. 4. Hypovolemic patients: Use of this product, especially after initial use, may cause symptomatic hypotension in patients with hypovolemic or hyposodium levels due to treatment with strong diuretics, a salt-restricted diet, nausea or vomiting. Therefore, blood sodium and blood volume levels should be corrected before use. 5. Other conditions associated with stimulation of the renin-angiotensin-aldosterone system: Use may affect the renin-angiotensin-aldosterone system in patients whose vascular tone and renal function are primarily dependent on the activity of the renin-angiotensin-aldosterone system, such as patients with severe congestive heart failure or renal disease including renal artery stenosis.

[Medication for Special Groups] Precautions for children:

Safety and efficacy data have not been established for children and adolescents under 18 years of age.



Precautions during pregnancy and lactation:

1. Use during pregnancy: There is insufficient data to show whether this product can be used in pregnant women. Animal tests did not show teratogenicity, but showed embryonic toxicity. Therefore, telmisartan should not be used in the first trimester as a precaution. Appropriate alternative therapies should be used before pregnancy is planned. Telmisartan is contraindicated in the second and third trimesters of pregnancy because drugs that directly target the renin-angiotensin system can cause fetal injury or death. This product should be discontinued as soon as pregnancy is confirmed. 2. Use during lactation: as it is still unknown whether this product is discharged through milk, it is forbidden during lactation.



Notes for the elderly:

There is no need to adjust the dosage.

[Drug interaction] 1. Lithium agent. Lithium in combination with angiotensin converting enzyme inhibitors can cause reversible elevated lithium levels and toxic reactions. A few cases were caused by the combination of lithium and angiotensin receptor antagonist. Therefore, lithium agent and this product should be used carefully. If concomitant use is required, blood potassium levels should be monitored during concomitant use. 2. Some medications can affect blood potassium levels or cause hyperkalemia (e.g., ACE inhibitors, potassium-conserving diuretics, potassium-ionic diuretics, potassium-ionic supplements, potassium-containing salt substitutes, cyclosporin A, or other medications such as heparin sodium); Monitoring blood potassium levels is recommended if this product is to be used in combination with these drugs. Based on experience with other agents that affect the renin-angiotensin system, the combination of these agents may cause an increase in serum potassium levels (see caution). 3. Pharmacokinetic tests have studied the interaction of this product with digoxin, warfarin, hydrochlorothiazide, glibenuron, ibuprofen, acetaminophen and amlodipine. Digoxin plasma peak concentration should be monitored for an increase in digoxin plasma peak concentration, which can increase digoxin plasma peak concentration by 20%(39% in a few cases). 4. This product can enhance the antihypertensive effect of other antihypertensive drugs. Other clinical interactions cannot be confirmed. 5. Based on its pharmacological properties, the following drugs may enhance the antihypertensive effect of telmisartan: baclofen, amifostine. In addition, alcohol, barbiturates, sedative sleeping pills, or antidepressants may enhance postural hypotension.

Telmisartan is a specific angiotensin receptor (AT type ) antagonist. Telmisartan replaces the angiotensin receptor and binds with high affinity to the AT receptor subtype (known angiotensin action site). Telmisartan has no site agonist effect on AT receptor sites, telmisartan selectively binds to AT receptor and this binding effect lasts for a long time. Telmisartan has no affinity for other receptors, including AT2 and other LESS characteristic AT receptors. The function of these other receptors is unknown, as is the possible overstimulation effect of telmisartan on angiotensin II levels. Telmisartan did not inhibit renin in human plasma or block ion channels. Telmisartan does not inhibit angiotensin converting enzyme ii, which can degrade the adverse effects of bradykinin enhancement. The elevated blood pressure induced by angiotensin was almost completely inhibited by telmisartan 80mg in human. The inhibitory effect lasted 24 hours and could still be detected at 48 hours. The antihypertensive effect of telmisartan gradually became apparent within 3 hours after the first dose. Maximum hypotensive effects are achieved 4 weeks after the start of treatment and can be maintained over the long term. If telmisartan treatment is abruptly discontinued, blood pressure gradually returns to pre-treatment levels after several days without rebound hypertension. In clinical trials that directly compared the two hypertensive drugs, the incidence of dry cough was significantly lower in patients treated with telmisartan than in those treated with angiotensin converting enzyme inhibitors.

[Storage] Shading, sealed storage.

[Specification] 40mg

[Packing specification] 40mg*14s/ box, 40mg*28s/ box, 40mg*21s/ box

[Validity] 48 months.

[Approval Number] Chinese medicine approval word H20041938


FAQ
1.who are we?
We are based in Fujian, China, start from 2000,sell to North America(40.00%),Southeast Asia(25.00%),Western Europe(25.00%),Africa(10.00%).There are total about 50 people in our office.

2. how can we guarantee quality?
Always a pre-production sample before mass production;
Always final Inspection before shipment;

3.what can you buy from us?
Pharmaceutical production lines,Intermediates,APIs,Finished Drug Preparations & Vaccines.

4. why should you buy from us not from other suppliers?
We have our own manufacture factories and one professional sales team working for the clients all over the world.

5. what services can we provide?
Accepted Delivery Terms: FOB,CIF,EXW,DDP,Express Delivery;
Accepted Payment Currency:USD,EUR,CAD,AUD,GBP,CNY;
Accepted Payment Type: T/T,L/C,PayPal,Western Union;
Language Spoken:English,Chinese,Japanese

Our Ddvantage:
1. Quick delivery
2. Online payment
3. Quality assurance
4. Welcome big order
5. After-sales service 24 hours
6. Competitive advantage products
7. Our value information is "Quality is our culture"
8. Work with us to provide you with secure funds, your business is securely protected, our advantages

Our Service
a)  Free amples can be provided.
b) Guide customers through professional technology and teach them how to use our products after sale
c) Determine the lowest price of high-quality products
1. Skilled experience: Our company is a leading manufacturer of professional production in China pharmaceutical field for many years.
2. The highest quality: to ensure high quality, once any problems are found, the package will be re-shipped for you.
3. Safe transportation: by air express (FedEx, UPS, DHL, EMS). It is recommended that you choose the most professional freight forwarder.
4. Fast delivery: We have stock, so once payment is received, we can deliver quickly.
5. Quality service: We will provide you with enthusiastic after-sales service. If you have any questions, we will reply to youwithin 24 hours.
6. Competitive price: discounts will be obtained when making large orders.

Our Manufacture Factory
Fuzhou FUL Fluid Equipment & Pharmaceutical Co., Ltd is a comprehensive enterprise which integrates R & D, production and construction of pharmaceutical production equipments, development and transfer of biotechnology, and cooperative production and sales of drugs and vaccines. The self-developed pharmaceutical production equipment branded FUL has been put into operation in many well-known pharmaceutical enterprises such as SINOPHARM, CSPC and also cooperates with many well-known pharmaceutical enterprises in production and sales, including pharmaceutical intermediates, APIs and finished drug preparations.

Fuzhou FUL Fluid Equipment & Pharmaceutical Co., Ltd business radiates to all levels, including direct supply cooperation with government departments and industry representatives, as well as establishing supply cooperation relationship with retail industry. We supply high quality, safe and effective medicines and medical equipment to governments, hospitals, clinics and licensed pharmacies in different countries with timely and effective services at reasonable prices.

At present Fuzhou FUL Fluid Equipment & Pharmaceutical Co., Ltd has the SINOPHARM authorization to sell its intermediates and APIs,and has the authorizations of CSPC & HUABEI PHARM sell its finished drug preparations;then FUL is the only manufacture in China which can supply the complete service from pharmaceutical produciton lines,intermediates and APIs to finished drug preparations and vaccines.Then we are seeking the professional pharmaceutical enterprices to work together for further cooperations.
 
Company Profile

 


Factory View

Telmisartan Tablets
Our Products

Telmisartan Tablets
Our Business
Telmisartan Tablets

Send your message to this supplier

*From:
*To:
*Message:

Enter between 20 to 4,000 characters.

This is not what you are looking for? Post a Sourcing Request Now

Find Similar Products By Category

Supplier Homepage Products BO MEI LAI VACCINE Telmisartan Tablets

Hot Searches

More

You Might Also Like

Product Groups

ITB Biopharm Co., Ltd.
Diamond Member Since 2020

Suppliers with verified business licenses

Rating: 4.5/5
Trading Company
Registered Capital
147802.18 USD
Plant Area
180 square meters
Hot Products China Products Chinese Manufacturers/Suppliers China Wholesale Wholesale Price Industry Sites Regional Channels Product Index Mobile Site
Language Options: Español Português Français Русский язык Italiano Deutsch Nederlands العربية 한국어 日本語 हिन्दी ภาษาไทย Türkçe Tiếng Việt Bahasa Indonesia
Copyright © 1998-2024 Focus Technology Co., Ltd. All Rights Reserved.
User Agreement Declaration Privacy Policy